CN116083286B - 一株婴儿双歧杆菌b8762及其制备益生菌制剂的用途 - Google Patents
一株婴儿双歧杆菌b8762及其制备益生菌制剂的用途 Download PDFInfo
- Publication number
- CN116083286B CN116083286B CN202211402937.2A CN202211402937A CN116083286B CN 116083286 B CN116083286 B CN 116083286B CN 202211402937 A CN202211402937 A CN 202211402937A CN 116083286 B CN116083286 B CN 116083286B
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium infantis
- preparation
- probiotic
- helicobacter pylori
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 title claims abstract description 92
- 229940004120 bifidobacterium infantis Drugs 0.000 title claims abstract description 89
- 239000006041 probiotic Substances 0.000 title claims abstract description 57
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 57
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 36
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 36
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- 239000000843 powder Substances 0.000 claims description 19
- 230000001580 bacterial effect Effects 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 13
- 239000003112 inhibitor Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000009629 microbiological culture Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract description 48
- 210000001072 colon Anatomy 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 10
- 235000013305 food Nutrition 0.000 abstract description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 230000000451 tissue damage Effects 0.000 abstract description 6
- 231100000827 tissue damage Toxicity 0.000 abstract description 6
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 230000000813 microbial effect Effects 0.000 abstract description 3
- 229960000074 biopharmaceutical Drugs 0.000 abstract description 2
- 235000013402 health food Nutrition 0.000 abstract description 2
- 238000009776 industrial production Methods 0.000 abstract description 2
- 230000007413 intestinal health Effects 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 16
- 239000002994 raw material Substances 0.000 description 14
- 239000012530 fluid Substances 0.000 description 12
- 230000002496 gastric effect Effects 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 235000009508 confectionery Nutrition 0.000 description 10
- 230000000968 intestinal effect Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- 235000013361 beverage Nutrition 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 238000002835 absorbance Methods 0.000 description 7
- 230000000770 proinflammatory effect Effects 0.000 description 7
- 230000037396 body weight Effects 0.000 description 6
- 235000013399 edible fruits Nutrition 0.000 description 6
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 6
- 150000003271 galactooligosaccharides Chemical class 0.000 description 6
- 239000001963 growth medium Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002207 metabolite Substances 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000002609 medium Substances 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 230000036285 pathological change Effects 0.000 description 4
- 231100000915 pathological change Toxicity 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 208000037816 tissue injury Diseases 0.000 description 4
- 108020004465 16S ribosomal RNA Proteins 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241001608472 Bifidobacterium longum Species 0.000 description 3
- 208000011231 Crohn disease Diseases 0.000 description 3
- 108090001005 Interleukin-6 Proteins 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 208000008469 Peptic Ulcer Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 229940009291 bifidobacterium longum Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000000832 lactitol Substances 0.000 description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 3
- 235000010448 lactitol Nutrition 0.000 description 3
- 229960003451 lactitol Drugs 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 235000020183 skimmed milk Nutrition 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 208000007882 Gastritis Diseases 0.000 description 2
- 206010019375 Helicobacter infections Diseases 0.000 description 2
- 102000003777 Interleukin-1 beta Human genes 0.000 description 2
- 108090000193 Interleukin-1 beta Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229920003045 dextran sodium sulfate Polymers 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 229940088592 immunologic factor Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- -1 and the like Substances 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 230000025938 carbohydrate utilization Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013400 design of experiment Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027138 indeterminate colitis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960003376 levofloxacin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000011450 sequencing therapy Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 238000009966 trimming Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/364—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins
- A23G3/366—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing microorganisms or enzymes; containing paramedical or dietetical agents, e.g. vitamins containing microorganisms, enzymes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/42—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds characterised by the carbohydrates used, e.g. polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明属于微生物益生菌剂技术领域，具体涉及一株婴儿双歧杆菌B8762，并进一步公开其制备益生菌制剂的用途，特别涉及其用于制备治疗炎症性肠病(IBD)及抑制幽门螺杆菌制剂的用途。本发明筛选并保存的婴儿双歧杆菌B8762菌株分离自健康婴儿肠道，能够改善炎症性肠病(IBD)，降低炎症反应、减少结肠组织损伤，并具有抑制幽门螺杆菌的作用。可用于制备改善肠道健康的益生菌制剂、普通食品、保健食品和生物制药，便于工业化生产，具有广阔的应用前景。
Description
技术领域
本发明属于微生物益生菌剂技术领域，具体涉及一株婴儿双歧杆菌B8762，并进一步公开其制备益生菌制剂的用途，特别涉及其用于制备治疗炎症性肠病(IBD)及抑制幽门螺杆菌制剂的用途。
背景技术
炎症性肠病(Inflammatory Bowel Disease，IBD)是一种以慢性炎症为特征的胃肠道疾病，主要包括克罗恩病(影响从口腔到肛门的胃肠道的任何部分)、溃疡性结肠炎(仅限于结肠黏膜)和不确定性结肠炎。与克罗恩病相比，溃疡性结肠炎直肠出血的发生频率更高，但克罗恩病患者通常会出现体重减轻和肛周疾病。既往IBD的发病因素被认为是由遗传、环境和免疫因素共同所致，但近年来研究发现，肠道菌群失调可能是UC及CD发生发展的重要诱因。近年来，炎症性肠病(IBD)发病率逐年上升，已成为全球性疾病，约有390万女性和300万男性患有该病。炎症性肠病(IBD)具有终身复发倾向，目前无特效治疗方法，急需寻找安全无副作用的微生物制剂。
幽门螺杆菌(helicobacter pylori，HP)是一种可黏附定植于胃黏膜表面的微需氧革兰阴性杆菌，是胃炎、消化性溃疡的致病性因素之一，已公认在胃溃疡、十二指肠溃疡、胃癌等病症中发挥了致因作用。此外，由幽门螺杆菌感染引发的胃炎还被认为是消化性溃疡及其相关并发症的危险因素。因此，消除幽门螺杆菌不仅可显著降低发生胃癌的风险，同时还可起到预防消化性溃疡的作用，而直接或间接性的提升幽门螺杆菌根除率，对防治幽门螺杆菌及其有关疾病的发生具有重要意义。目前，传统用于根除HP的治疗方案主要为含铋剂的四联方案，而新的治疗方案如序贯疗法、左氧氟沙星疗法等，主要是通过抗生素结合的三联或者四联疗法以清除患者体内的幽门螺杆菌以恢复幽门螺杆菌感染导致的胃肠症状。但是，由于治疗过程需要联合应用多种抗生素，不仅疗程较长，且常常导致耐药、菌群失调、依从性下降等副作用，患者出现不良反应的几率极大，并降低了治疗效率。大量临床实践证实，临床上治疗幽门螺杆菌时结合口服肠道益生菌可起到一定的正向辅助效果。
婴儿双歧杆菌是肠道内的正常有益菌群，其代谢产物--短链脂肪酸对多种肠道局部免疫细胞具有免疫调节作用，大量临床实践证实，临床上治疗幽门螺杆菌时口服肠道益生菌也可起到一定效果，而消除幽门螺杆菌不仅可显著降低发生胃癌的风险，同时还在缓解炎症性肠病(IBD)中扮演重要角色。因此，开发可辅助治疗炎症性肠病(IBD)并可抑制幽门螺杆菌的益生菌制剂，对调节人体免疫力及改善肠道功能具有积极的意义。
发明内容
为此，本发明的第一个目的在于提供一株婴儿双歧杆菌B8762，所述菌株对于治疗炎症性肠病及抑制幽门螺杆菌具有较好的作用；
本发明的第二个目的在于提供上述婴儿双歧杆菌B8762及其灭活物、代谢物用于制备益生菌制剂的用途；
本发明的第三个目的在于提供一种幽门螺杆菌抑制剂。
为解决上述技术问题，本发明所述的一株婴儿双歧杆菌B8762，其分类命名为长双歧杆菌婴儿亚种Bifidobacterium longum subsp.infantis，已保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCCNo.22765，保藏日期为2021年6月23日。
本发明还公开了所述的婴儿双歧杆菌B8762及其灭活物、代谢物用于制备益生菌制剂的用途。
在本发明方案中，所述灭活物包括但不限于灭活的菌体、发酵产物、培养物等经常规灭活处理的物质，所述代谢物包括但不限于经培养、发酵、代谢、提取所得物质。
本发明还公开了一种益生菌制剂，所述益生菌制剂的活性成分包括所述的婴儿双歧杆菌B8762的菌体、灭活物和/或代谢物。
具体的，所述益生菌制剂中，所述婴儿双歧杆菌B8762的有效菌体数量为不少于1×106CFU/mL或者1×106CFU/g。
具体的，所述益生菌制剂在液体、半固体和固体中的任何状态均可发挥健康作用。具体的，所述益生菌制剂包括散剂、颗粒剂、丸剂、胶囊剂、片剂、膏剂、液体制剂、凝胶剂、喷雾剂、固体饮料中的至少一种。
本发明还公开了一种制备所述益生菌制剂的方法，包括将所述的婴儿双歧杆菌B8762进行菌体培养的步骤，以及按照常规工艺、添加常规辅料进行选定剂型加工的步骤。
前述“常规工艺”包括但不限于传统的工艺手段，诸如压片、分散、造粒等本领域常规的制剂手段；前述“常规辅料”包括但不限于本领域已知的辅料载体、赋形剂、佐剂、粘合剂、溶剂等种类及原料成分。
本发明还公开了所述的婴儿双歧杆菌B8762及其灭活物、代谢物或者所述益生菌制剂用于制备具有如下(1)-(5)中至少一项功效的功能性产品的用途：
(1)对幽门螺杆菌具有抑制作用；
(2)可预防、缓解和/或治疗炎症性肠病(IBD)；
(3)降低血液促炎因子药物；
(4)减少结肠组织损伤药物中；
(5)降低血液炎症反应和/或降低促炎细胞因子浓度；优选的，所述促炎细胞因子包括肿瘤坏死因子-α和/或白细胞介素-1β。
具体的，所述功能性产品包括功能性食品、药品、保健品、功能性护理产品或功能性辅助材料；如日常可见的发酵制品、普通食品、保健食品以及医药制剂产品等。
优选的，所述食品包括固体食品或液体食品。
本发明还公开了一种幽门螺杆菌抑制剂，所述抑制剂活性成分包括所述的婴儿双歧杆菌B8762的菌体、灭活物和/或代谢物。
所述幽门螺杆菌及炎症性肠病治疗制剂可以为散剂、片剂、胶囊剂、口服液体剂型、颗粒剂、软膏剂或其他等。所述幽门螺杆菌及炎症性肠病治疗制剂中还可以包括药学上可接受的其它辅料。
具体的，所述的幽门螺杆菌抑制剂，所述抑制剂中，所述婴儿双歧杆菌B8762的有效菌体数量为不少于2×106CFU/mL或者2×106CFU/g。
在一种可实现的方式中，所述婴儿双歧杆菌B8762还可以用于制备复配食品，所述复配食品由向食品基底中添加所述婴儿双歧杆菌B8762而得，并且，在添加所述婴儿双歧杆菌B8762后，不经发酵等进一步处理。
在一种可实现的方式中，所得复合食品中所复配的婴儿双歧杆菌B8762可以其菌粉形式添加，也可以其它形式添加，例如，包括所婴儿双歧杆菌B8762活菌和死菌的制剂。
可选地，基于所述复配食品的总重量或者总体积，其中，所述婴儿双歧杆菌B8762的数量为1×106CFU/mL或者1×106CFU/g以上。
本发明筛选并保存的婴儿双歧杆菌B8762菌株分离自健康婴儿肠道，能够改善炎症性肠病(IBD)，降低炎症反应、减少结肠组织损伤，并具有抑制幽门螺杆菌的作用。本发明所述婴儿双歧杆菌B8762菌株来源清晰、功效明确，可用于制备改善肠道健康的益生菌制剂、普通食品、保健食品和生物制药，便于工业化生产，具有广阔的应用前景。
本发明方案以患有炎症性肠病的6周龄雄性Wistar大鼠进行的体内研究发现，本发明筛选并保存的婴儿双歧杆菌B8762菌株能够降低促炎因子、减少结肠组织损伤症状，对炎症性肠病具有改善作用，尤其是体外试验进一步证实该菌株对幽门螺杆菌具有一定的抑制能力，应用前景广泛。
附图说明
为了使本发明的内容更容易被清楚的理解，下面根据本发明的具体实施例并结合附图，对本发明作进一步详细的说明，其中，
图1为婴儿双歧杆菌B8762治疗炎症性肠病分组设计；
图2为婴儿双歧杆菌B8762显著降低IBD导致的体重减轻症状结果；
图3为婴儿双歧杆菌B8762显著降低血清炎症反应结果；
图4为实验组大鼠结肠病理组织图像(×200)；
图5婴儿双歧杆菌B8762显著降低IBD大鼠结肠组织损伤结果。
具体实施方式
本发明如下实施例通过具体方案对本申请提供婴儿双歧杆菌B8762及其应用进行详细阐述。
本发明如下实施例中：
活菌计数的方法采用倾注平板计数法，具体操作步骤为：依据GB 4789.35-2016方法检测；
测定益生菌活菌数所用的培养基为改良MRS培养基，其成分为：细菌学蛋白胨10g/L、牛肉浸粉8g/L、酵母浸粉4g/L、葡萄糖20g/L、Tween-80 1mL、K2HPO4 2g/L、醋酸钠·3H2O5g/L、柠檬酸三铵2g/L、MgSO4·7H20 0.2g/L、MnSO4·5H20 0.05g/L、纯化水1000mL、琼脂15g/L。所述改良MRS合成培养基购买自广东环凯微生物科技有限公司，微生物检测用。
实施例1婴儿双歧杆菌B8762的分离、筛选与鉴定
本实施例所述婴儿双歧杆菌B8762通过以下方法分离得到：自健康婴儿肠道样品，称取0.5g样品用4.5mL无菌PBS稀释后，取0.1mL涂布于改良MRS固体培养基，37℃厌氧培养72h。挑取典型菌落进行革兰氏染色镜检挑选后，选取革兰氏阳性菌株，再划线于改良MRS固体培养基2-3次培养得到纯菌落。
本菌株显微镜下观察形态为革兰氏阳性菌，无鞭毛、不运动，不形成芽孢，厌氧；菌体呈杆状且形态多样、多呈V型、Y型或棒球型；在改良MRS固体培养基上，菌落光滑且边缘完整，呈奶油白色且不透明。最适生长温度为36℃-38℃；最适pH值为6.0-7.0。
对分离到的菌株进行生理生化鉴定和16S rRNA分子鉴定，根据《伯杰细菌鉴定手册》，使用细菌API50CH(生物梅里埃公司)进行鉴定，结果见表1。
表1婴儿双歧杆菌B8762碳水化合物利用结果
提取该菌株的DNA样品，样品经上海美吉生物医药科技有限公司进行16S rRNA分子鉴定，分子序列经NCBI数据库blastn比对，确认B8762为婴儿双歧杆菌，其16S rRNA序列如SEQ ID No.1所示，命名为婴儿双歧杆菌(Bifidobacterium longum subsp.infantis)B8762。
该菌株已保藏于中国微生物菌种保藏管理委员会普通微生物菌种保藏中心，其微生物保藏编号为：CGMCC No.22765，分类命名为：长双歧杆菌婴儿亚种Bifidobacteriumlongum subsp.infantis，保藏时间：2021年6月23日，保藏地址：中国北京市朝阳区北辰西路1号院3号，中国科学院微生物研究所。
实施例2婴儿双歧杆菌B8762胃肠液耐受性能
在pH2.5(用1mol/L HCl调整)灭菌PBS中，加入3.5g/L胃蛋白酶，用0.22μm的微孔滤膜过滤除菌，制成模拟胃液。
选择经耐酸性筛选后的菌株进行培养，培养两代后离心洗菌两次，收集菌体，加入与培养基等量的pH2.5模拟胃液，37℃厌氧培养3h，于0h、3h用改良MRS琼脂培养基倾注法测定其活菌数。
在pH8.0(用0.1mol/L NaOH调整)灭菌PBS中，加入0.1％胰蛋白酶和1.8％牛胆盐用0.22μm的微孔滤膜过滤除菌，制成模拟肠液。
将模拟胃液中处理3h后的菌液，离心洗菌两次收集菌体后，加入与之前模拟胃液等量的模拟肠液继续37℃厌氧培养，于0h、4h、8h用改良MRS琼脂培养基倾注法测活菌数。
存活率＝[N1/N0]×100％；
其中，N0表示0h活菌数；N1表示经模拟消化3h或8h后的活菌数。
本实施例中，所述婴儿双歧杆菌B8762经模拟胃液和模拟肠液处理后，结果如下表2所示。
表2婴儿双歧杆菌B8762模拟胃肠消化液存活情况
| 菌株 | 模拟胃液(pH2.5,3h)存活率(％) | 模拟肠液(pH8.0,8h)存活率(％) |
| B8762 | 77.04 | 60.33 |
由表2数据可知，本发明筛选的所述婴儿双歧杆菌B8762具有良好的耐受特性，在模拟肠液处理8小时后存活率可达60.33％。而根据本实施例胃肠液耐受效果可知，婴儿双歧杆菌B8762在肠道中具有良好的耐受胃肠液的特点，具有益生特性。
实施例3婴儿双歧杆菌B8762对炎症性肠病的治疗作用
实验菌株制剂
取保存的婴儿双歧杆菌B8762制剂，菌体细胞含量2×1011CFU/g，成分为婴儿双歧杆菌B8762冻干粉，麦芽糊精)，由北京科拓恒通生物技术股份有限公司提供。
实验设计
本实施例具体实施设计方案如图1所示。
选择6周龄雄性Wistar大鼠，体重在190g-210g之间，适应一周后随机分为4组，每组12只，正常组、模型组、婴儿双歧杆菌B8762活菌组和婴儿双歧杆菌B876死菌组。适应1周后，使用3％葡聚糖硫酸钠(DSS)诱导炎症性肠病(IBD)，造模周期7天。造模结束后，正常组和模型组灌胃2.5mL生理盐水，婴儿双歧杆菌B8762活菌组和婴儿双歧杆菌B876灭活组大鼠分别灌胃2.5mL的B8762溶液(2×109CFU/只)，14天后处死。
体重监测
监测造模结束后初始体重(0d)和干预14d后的体重，称量每只鼠的重量，计算平均体重，具体结果见图2。
可见，葡聚糖硫酸钠诱导炎症性肠病小鼠会出现体重下降的情况，持续灌胃活或灭活B8762 14天后，与模型组相比，活的或灭活的婴儿双歧杆菌B8762组均可显著提高IBD大鼠体重(P<0.05)。
上述研究表明，婴儿双歧杆菌B8762能够有效降低炎症性肠病带来的体重减轻症状。
免疫因子测定
收集大鼠血清，使用离心机4℃条件下，3000g离心10min，收集上清液分装，每个1.5mL灭菌离心管100uL上清液，尽快置于-80℃冰箱冷冻备用。使用酶联免疫试剂盒测量抗炎因子IL-10，促炎因子IL-1β、IL-6和TNF-α含量，具体结果见图3。
可见，炎症细胞因子在IBD的发病机制中起到至关重要的作用，与模型组相比，灭活和活的婴儿双歧杆菌B8762均可降低IBD大鼠血清中的IL-1β和TNF-α含量，而只有活的婴儿双歧杆菌B8762能够显著降低IL-6含量；对于抗炎因子IL-10，灭活和活的婴儿双歧杆菌B8762均未起到作用。
上述研究表明，婴儿双歧杆菌B8762能够有效降低炎症反应，有效治疗改善炎症性肠病。
结肠组织病理学分析
取14天的结肠样本，经4％多聚甲醛固定，固定状态良好后，进行修剪、脱水、包埋、切片、染色、封片，最后镜检合格的样片。在显微镜下浏览切片在不同倍数下详细观察组织切片病理改变(充血、淤血、出血、水肿、变性、坏死、增生、纤维化、机化、肉芽组织、炎性变化)情况，在显微镜下仔细观察每张组织切片并记录组织学变化，并进行组织评分。组织病变程度采用五级分法，无病变或极少量病变计分为0；有轻度病变或少量病变计分为1；有中度病变或中等量病变计分为2；有重度病变或多量病变计分为3；有极重度病变或大量病变计分为4。
图4为实验组大鼠结肠病理组织图像(×200)，图5为所述婴儿双歧杆菌B8762显著降低IBD大鼠结肠组织损伤结果。可见，与模型组比较，活的或灭活的婴儿双歧杆菌B8762组粘膜层肠上皮细胞形态结构正常，固有层与粘膜下层的水肿较少，婴儿双歧杆菌B8762可显著改善IBD大鼠结肠组织损伤。
上述研究表明，婴儿双歧杆菌B8762能降低及减轻炎症性肠病带来的结肠组织损伤症状。
统计分析
与模型组相比，婴儿双歧杆菌B8762活菌和死菌干预对IBD大鼠的改善作用具有显著性(p<0.05)。具体表现为：
1)有效改善IBD大鼠结肠组织损伤(p<0.05，p<0.01)，提高体重；
2)上调抑炎症细胞因子IL-10的分泌，下调促炎细胞因子IL-1β、IL-6及TNF-α(p<0.05)的分泌，缓解IBD引起的肠道炎症。
使用SPSS软件分析数据，此项研究主要涉及益生菌和模型组之间的功效差异。考虑到我们数据的偏态分布和非参数性质，使用曼-惠特尼检验比较益生菌和模型组之间或两个不同时间点之间的数据差异；使用卡方检验比较数据。除非另有说明，否则所有测试均为具有P<0.05统计学意义，并且数据均以平均值±标准误差表示。
实施例4婴儿双歧杆菌B8762菌株自凝集能力测定
菌株制备菌悬液，用酶标仪调节OD600nm＝0.5±0.05后，取1mL菌悬液于灭菌的1.5mL离心管中，室温静置培养，分别在静置1h、2h、3h、4h、5h、6h、24h和48h后吸取上层液体，测试600nm处的吸光值，计算自凝集率(％)，计算公式如下：
式中：A0：菌株自凝集前在600nm的初始吸光值；
At：静置t小时后在600nm的吸光值。
所述婴儿双歧杆菌B8762菌株自凝集能力测定结果见下表3。
表3婴儿双歧杆菌B8762不同时间自凝集率(N＝3)
由表1数据可知，随时间延长，菌株表面自凝聚能力增强。静置24h后，婴儿双歧杆菌B8762菌株显示出了较高的自凝集能力，达到90.0％以上。
实施例5婴儿双歧杆菌B8762菌株与幽门螺杆菌的交互凝集能力
取B8762菌株和幽门螺杆菌制备菌悬液，用酶标仪调节OD600nm＝0.5±0.05后，取等量的B8762菌株和幽门螺杆菌菌悬液混合于灭菌的1.5mL离心管中，彻底振荡5min，室温静置培养，分别在静置1h、2h、3h、4h、5h、6h、24h和48h后吸取上层液体，测试600nm处的吸光值，计算交互凝集率(％)，公式如下：
式中：Ax：交互凝集前在600nm处B8762菌株的吸光值；
Ay：交互凝集前幽门螺杆菌在600nm处的吸光值；
Amin：静置t小时后混合菌液的吸光值。
所述婴儿双歧杆菌B8762菌株与幽门螺杆菌交互凝集能力测定结果见下表4。
表4婴儿双歧杆菌B8762与幽门螺杆菌交互凝集率(N＝3)
由表4数据可知，随着静置时间延长，婴儿双歧杆菌B8762菌株与幽门螺杆菌的交互凝集力也增强。静置24h后，交互凝集率达到90.0％以上。
综上，本发明所述婴儿双歧杆菌B8762持续干预2周能够显著抑制幽门螺杆菌并改善炎症性肠病(IBD)症状，显著缓解体重下降、降低促炎因子、减少结肠组织损伤，婴儿双歧杆菌B8762对炎症性肠病具有治疗作用；且所述婴儿双歧杆菌B8762菌株具有较稳定的拮抗幽门螺杆菌能力，对抑制幽门螺杆菌具有较好的作用。
实施例6
本实施例所述益生菌固体饮料的原料质量配比为：婴儿双歧杆菌菌粉5重量份、水果粉32重量份、低聚半乳糖18重量份、乳糖醇4.5重量份、麦芽糊精30重量份。
本实施例所述益生菌固体饮料的制备方法包括：将上述原料按比例配制并过80目筛；将过筛后的所述原料倒入混合机，转速900r/h，混合时间30min，充分混匀；将混匀后的所述原料倒入灌装设备，进行灌装塑封，得到益生菌固体饮料。
本实施例所述益生菌固体饮料，所述益生菌固体饮料中，益生菌活菌数大于1010CFU/g。
实施例7
本实施例所述益生菌固体饮料的原料质量配比为：婴儿双歧杆菌菌粉4重量份、水果粉40重量份、低聚半乳糖15重量份、乳糖醇5重量份、麦芽糊精25重量份。
本实施例所述益生菌固体饮料的制备方法同实施例6。
本实施例所述益生菌固体饮料，所述益生菌固体饮料中，益生菌活菌数大于1010CFU/g。
实施例8
本实施例所述益生菌固体饮料的原料质量配比为：婴儿双歧杆菌菌粉6重量份、水果粉25重量份、低聚半乳糖20重量份、乳糖醇4重量份、麦芽糊精35重量份。
本实施例所述益生菌固体饮料的制备方法同实施例6。
本实施例所述益生菌固体饮料，所述益生菌固体饮料中，益生菌活菌数大于1010CFU/g。
实施例9
本实施例所述益生菌压片糖果的原料质量配比为：婴儿双歧杆菌菌粉4.5重量份、脱脂奶粉25重量份、水果粉25重量份、低聚半乳糖12重量份、木糖醇4.5重量份、微晶纤维素8重量份、硬脂酸镁0.8重量份。
本实施例所述益生菌压片糖果的制备方法包括：将上述原料按比例配制；将配制后的所述原料倒入混合机，转速900r/h，混合时间30min，充分混匀；将混合后的所述原料通入筛选机，在80目筛下进行过筛；将过筛后的所述原料通入压片机，进行压片，得到益生菌压片糖果。
本实施例所述益生菌压片糖果中，益生菌活菌数大于109CFU/g。
实施例10
本实施例所述益生菌压片糖果的原料质量配比为：婴儿双歧杆菌菌粉4重量份、脱脂奶粉30重量份、水果粉20重量份、低聚半乳糖15重量份、木糖醇4重量份、微晶纤维素10重量份、硬脂酸镁0.5重量份。
本实施例所述益生菌压片糖果的制备方法同实施例9。
本实施例所述益生菌压片糖果中，益生菌活菌数大于109CFU/g。
实施例11
本实施例所述益生菌压片糖果的原料质量配比为：婴儿双歧杆菌菌粉5重量份、脱脂奶粉20重量份、水果粉30重量份、低聚半乳糖10重量份、木糖醇5重量份、微晶纤维素5重量份、硬脂酸镁1重量份。
本实施例所述益生菌压片糖果的制备方法同实施例9。
本实施例所述益生菌压片糖果中，益生菌活菌数大于109CFU/g。
显然，上述实施例仅仅是为清楚地说明所作的举例，而并非对实施方式的限定。对于所属领域的普通技术人员来说，在上述说明的基础上还可以做出其它不同形式的变化或变动。这里无需也无法对所有的实施方式予以穷举。而由此所引伸出的显而易见的变化或变动仍处于本发明创造的保护范围之中。
Claims (8)
1.一株婴儿双歧杆菌B8762，其特征在于，其分类命名为长双歧杆菌婴儿亚种Bifidobacterium longum subsp.infantis，已保藏于中国微生物菌种保藏管理委员会普通微生物中心，保藏编号为CGMCC No.22765，保藏日期为2021年6月23日。
2.权利要求1所述的婴儿双歧杆菌B8762及其灭活物用于制备益生菌制剂的用途。
3.一种益生菌制剂，其特征在于，所述益生菌制剂的活性成分包括权利要求1所述的婴儿双歧杆菌B8762的菌体和/或灭活物；
所述益生菌制剂中，所述婴儿双歧杆菌B8762的有效菌体数量为不少于1×106CFU/mL或者1×106CFU/g。
4.根据权利要求3所述的益生菌制剂，其特征在于，所述益生菌制剂包括散剂、颗粒剂、丸剂、胶囊剂、片剂、膏剂、液体制剂、凝胶剂、喷雾剂中的至少一种。
5.一种制备权利要求3或4所述益生菌制剂的方法，其特征在于，包括将权利要求1所述的婴儿双歧杆菌B8762进行菌体培养的步骤，以及按照常规工艺、添加常规辅料进行选定剂型加工的步骤。
6.权利要求1所述的婴儿双歧杆菌B8762及其灭活物或者权利要求3或4所述益生菌制剂用于制备对幽门螺杆菌具有抑制作用的功能性产品的用途。
7.一种幽门螺杆菌抑制剂，其特征在于，所述抑制剂的活性成分为权利要求1所述的婴儿双歧杆菌B8762的菌体和/或灭活物。
8.根据权利要求7所述的幽门螺杆菌抑制剂，其特征在于，所述抑制剂中，所述婴儿双歧杆菌B8762的有效菌体数量为不少于2×106CFU/mL或者2×106CFU/g。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211402937.2A CN116083286B (zh) | 2022-11-08 | 2022-11-08 | 一株婴儿双歧杆菌b8762及其制备益生菌制剂的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211402937.2A CN116083286B (zh) | 2022-11-08 | 2022-11-08 | 一株婴儿双歧杆菌b8762及其制备益生菌制剂的用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116083286A CN116083286A (zh) | 2023-05-09 |
| CN116083286B true CN116083286B (zh) | 2023-08-25 |
Family
ID=86205307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211402937.2A Active CN116083286B (zh) | 2022-11-08 | 2022-11-08 | 一株婴儿双歧杆菌b8762及其制备益生菌制剂的用途 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116083286B (zh) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108220206A (zh) * | 2018-03-12 | 2018-06-29 | 江南大学 | 一种长双歧杆菌及其应用 |
| CN114574390A (zh) * | 2022-03-09 | 2022-06-03 | 江南大学 | 一株缓解结肠炎的长双歧杆菌婴儿亚种及应用 |
-
2022
- 2022-11-08 CN CN202211402937.2A patent/CN116083286B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108220206A (zh) * | 2018-03-12 | 2018-06-29 | 江南大学 | 一种长双歧杆菌及其应用 |
| CN114574390A (zh) * | 2022-03-09 | 2022-06-03 | 江南大学 | 一株缓解结肠炎的长双歧杆菌婴儿亚种及应用 |
Non-Patent Citations (1)
| Title |
|---|
| Beneficial effects of Bifidobacterium longum subsp. longum BB536 on human health: Modulation of gut microbiome as the principal action;Chyn Boon Wong et al;Journal of Functional Foods;第506-519页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116083286A (zh) | 2023-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11116806B2 (en) | Composite probiotic lactic acid bacteria powder and preparation method and use thereof | |
| JP6837015B2 (ja) | たとえば、細菌性膣炎の治療のためのＬａｃｔｏｂａｃｉｌｌｕｓ ｒｈａｍｎｏｓｕｓ（ラクトバチルス・ラムノサス）細菌 | |
| US9649347B2 (en) | Protective effects and application of a Lactobacillus rhamnosus on the alleviation of chronic alcoholic liver injury | |
| CN116731891B (zh) | 一株短双歧杆菌b2798及其制备益生菌制剂的用途 | |
| CN116004483B (zh) | 一种预防或治疗腹泻的格氏乳球菌及其应用 | |
| CN116200306B (zh) | 一种鼠李糖乳酪杆菌LRa16及其在制备治疗生殖道感染的药物方面的用途和产品 | |
| CN113197250B (zh) | 一种含嗜热链球菌mn002的产品的用途及乳制品 | |
| CN113943681B (zh) | 一株降低炎症反应且具有缓解便秘作用的长双歧杆菌 | |
| EP3808357A1 (en) | Composition and uses thereof | |
| CN116121154B (zh) | 一种乳明串珠菌及其应用 | |
| CN116083325B (zh) | 一种改善幽门螺杆菌相关性胃肠疾病的鼠李糖乳杆菌及其应用 | |
| WO2018112741A1 (zh) | 一种嗜酸乳杆菌及其培养方法和应用 | |
| CN114774315B (zh) | 鼠李糖乳杆菌菌株LRa05在制备增强免疫力制品和/或缓解湿疹制品方面的用途 | |
| CN113005067A (zh) | 多功能复合益生菌制剂及其制备方法 | |
| CN111471626A (zh) | 一株能够抑制幽门螺杆菌的瑞士乳杆菌及其应用 | |
| WO2018112740A1 (zh) | 一种加氏乳杆菌及其培养方法和应用 | |
| CN116083286B (zh) | 一株婴儿双歧杆菌b8762及其制备益生菌制剂的用途 | |
| CN113005066A (zh) | 抗过敏、增加免疫力、降血糖、降脂减肥的复合双歧杆菌制剂及其制备方法 | |
| CN114874954B (zh) | 一种能够促进肠道中短链脂肪酸产生的弯曲乳杆菌及其应用 | |
| CN113699061B (zh) | 一株可缓解溃疡性结肠炎的菌株Phocaeicola sp.及其应用 | |
| CN115029270B (zh) | 一株能够降低肠道促炎细胞因子的清酒乳杆菌及其应用 | |
| CN116574634B (zh) | 一株唾液链球菌嗜热亚种jf2及其在制备抗炎和解脂食品药品中的应用 | |
| CN116478874B (zh) | 一种改善慢性低度炎症的副干酪乳杆菌及其应用 | |
| CN117286045B (zh) | 一株长双歧杆菌长亚种ks2及其在制备抗衰老药品中的应用 | |
| CN117159598B (zh) | 植物乳植杆菌Lp18在制备增强免疫的药物或保健食品方面的用途及产品 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |